Our initial interest was to quantify various angiogenic mediators (HIF1α, VEGF, TGFβ etc) and some typical immunosuppression signatures (type 2 cytokines, Tregs, MDSCs etc) in the microenvironment of sarcoma tumors and correlate their abundance to the impairment of cytotoxic T lymphocytes, as the presence of impaired T cells in tumor vicinity has been reported as a pivotal sign of poor prognosis in many cancer types [34]. The gene discussed is TGFB1; the disease is cancer.